4 results
Approved WMOCompleted
Primary: to assess the longterm safety and tolerability of ambrisentan 5mg in subjects with inoperable CTEPH. Secondary: to collect supportive efficacy data.
Approved WMOWill not start
Primary: Longterm safety and tolerability of 2 dosages of ambrisentan. Secundary: Supportive efficacy data.
Approved WMOWill not start
Primary: Safety and tolerability of 2 dosages of ambrisentan. Secundary: Efficacy and PK.
Approved WMOCompleted
The primary objective of this study is to compare the two treatment strategies; first-line combination therapy (ambrisentan and tadalafil) versus first-line monotherapy (ambrisentan or tadalafil) in subjects with PAH. This will be assessed by time…